

O I P E
SEP 19 2005
Substitute for form 1449/PTO
PATENT & TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1



Application Number	10/479,323
Filing Date	December 31, 2003
First Named Inventor	Rey-Yuh Wu
Art Unit	1642
Examiner Name	Not Assigned

Attorney Docket Number

03-1119

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JK	1	Shenqi Strengthen Injection, Http://tumor.cn/otc/show.php?id+98, January 28, 2005 (English Translation)	✓
JK	2	Kurashige, S., et al. "Effects of Astragalus Radix Extract on Carcinogenesis, Cytokine Production and Cytotoxicity in Mice Treated with a Carcinogen, N-Butyl-N".	
JK	3	Butanolnitrosoamine", Cancer Invest. Vol. 17, No. 1 30-5, 1981 (Abstract only)	
JK	4	Lin, SY, et al., "Protection by Quercetin Against Cooking Oil Fumes-induced DNA Damage in Human Lung Adenocarcinoma CL-3 Cells: Role of COX-2, Nutr Cancer, Volume 44, No. 1, 95-101, 2002 (Abstract Only)	

Examiner Signature		Date Considered	
--------------------	---	-----------------	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-1119	Serial No. 10/749,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>		Applicant: Wu et al.	
		Filing Date: December 31, 2003	Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JK	✓	4,618,495	10/21/86	Okuda et al.			
JK	✓	4,843,067	6/27/89	Liu			
JK	✓	4,999,343	3/12/91	Liu			
JK	✓	5,268,467	12/7/93	Verbiscar			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
JK	EP 441 278 A1	8/14/91	EP				
JK	WO 94/04162	3/3/94	PCT				
JK	* CN 1075886A (with abstract)	9/8/93	CN				
JK	* CN 1100654A (with abstract)	3/29/95	CN				
JK	* CN 1106274A (with abstract)	8/8/95	CN				
JK	* CN 1205880A (with abstract)	1/27/99	CN				
JK	* CN 1330082A (with abstract)	1/9/02	CN				
JK	* JP 5039305 (with abstract)	2/19/93	JP				

EXAMINER <i>Brenton W. M.</i>	DATE CONSIDERED <i>2/21/2004</i>
-------------------------------	----------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

* Did not receive these patents.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-1119	Serial No. 10/749,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use several sheets if necessary)			
		Applicant: Wu et al.	
		Filing Date: December 31, 2003	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

<i>BF</i>	Lau, et al., "Chinese Medicinal Herbs Inhibit Growth of Murine Renal Cell Carcinoma", <i>Cancer Biotherapy</i> , Vol. 9, No. 24, pp. 153-161 (1994).
<i>BF</i>	Rittenhouse, et al. "Chinese Medicinal Herbs Reverse Macrophage Suppression Induced by Urological Tumors, <i>The Journal of Urology</i> , Vol. 146, pp. 486-490 (1991).
<i>BF</i>	Wong et al., "Chinese Medicinal Herbs Modulate Mutagensis, DNA Binding and Metabolism of Aflatoxin B ₁ " <i>Mutation Research</i> , Vol. 279, pp. 209-216 (1992).
<i>BF</i>	Tang et al., "Recent Development of Antitumor Agents from Chinese Herbal Medicines. Part II. High Molecular Compounds", <i>Planta Med.</i> , Vol. 69, pp. 193-201 (2002).
<i>BF</i>	Xue, et al. "The Effect of Astragapolysaccharide on the Lymphocyte Proliferation and Airway Inflammation in Sensitized Mice", <i>Journal of Tongji Medical University</i> , Vol. 19, pp. 20-22 (1999).
<i>BF</i>	Yoshida, et al. "Immunomodulating Activity of Chinese Medicinal Herbs and Oldenlandia Diffusia in Particular", <i>Int. J. Immunopharmac.</i> , Vol. 19, pp. 359-370, (1997)
<i>BF</i>	Chen, "Experimental Studies on the Effects of Danggui Buxue Decoctionon IL-2 Production of Blood-Deficient Mice", <i>Zhongguo Zhong Yao Za Zhi</i> , Vol. 19, pp. 739-741 (1994). (with abstract)
<i>BF</i>	Shimizu, "An Acidic Polysaccharide Having Activity on the Reticuloendothelial System from the Root of Astragalus Mongolicus" <i>Chem. Pharm. Bull.</i> Vol. 39, pp. 2969-2972 (1991).
<i>BF</i>	Wang, et al., "Immunomodulatory Effect of A Polysaccharide-Enriched Preparation of Conconopsis Polisula Roots", <i>Gen. Pharmac.</i> Vol. 27, pp. 1347-1350 (1996).
<i>BF</i>	Shan, et al., "Stimulating Activity of Chinese Medicinal Herbs on Human Luymphocytes in Vitro", <i>International Journal of Immunopharmacology</i> , Vol. 21, pp. 149-159 (1999).
<i>BF</i>	Chen et al., "The Effects of Chinese Herbs on Improving Survival and Inhibiting anti-ds DNA antibody production in Lupus Mice", <i>American Journal of Chinese Medicine</i> , Vol. XXI, pp. 257-262 (1993).
<i>BF</i>	Zhang, et al. "Studies of Polysaccharides of Codonopsis Pilosula", <i>Zheng Zao Yea</i> , Vol. 18, pp. 2-4 (1987)

EXAMINER 	DATE CONSIDERED <i>2/21/2006</i>
--	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.